growth - The 17% revenue growth, 46% net income growth, and 50% EPS growth attract growth-oriented investors seeking small-cap healthcare…
Rising interest rates have minimal direct impact on operations given zero debt and strong cash generation ($0.0B operating cash flow appears…
Watch on earnings: Medicare Physician Fee Schedule updates for HFCWO therapy codes (E0483, E0484) - typically announced in November for following year implementation, Cystic fibrosis patient population trends and CFTR modulator drug adoption rates (Vertex Pharmaceuticals' Trikafta) - gene therapies may reduce disease severity and HFCWO need, Bronchiectasis prevalence data and diagnosis rates - estimated 340,000-500,000 US patients but significant underdiagnosis represents growth opportunity.
One Sentence Summary:
Electromed: the story is balanced — quarterly device placement volumes and average selling prices (asps) - unit growth drives topline expansion.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
